DIOSynVax is a Cambridge-based company with a focus on developing technology to accelerate the development of vaccines for illnesses. Its name stands for Digitally designed, Immune Optimized Selected and Synthesized Vaccines. It is supported by Cambridge Enterprise, which is the commercialization arm of the University of Cambridge. The company states that the new technology will accelerate vaccine development and achieve improvements to the protection against emerging and re-emerging pathogens such as influenza, COVID-19, and viral hemorrhagic fevers.
During the COVID-19 pandemic in 2020, the company conducted research to understand the genetic make-up of the virus. It intends to use a combination of artificial intelligence and synthetic biology to develop a vaccine for COVID-19.
Dr. Jonathan Heeney
Dr. Rebecca Kinsley
Cambridge University spin-out working on COVID-19 vaccine seeks Big Pharma alliance | Business Weekly | Technology News | Business news | Cambridge and the East of England
March 17, 2020
The race for a COVID-19 vaccine
Documentaries, videos and podcasts
Behind the scenes at the lab developing coronavirus vaccine
March 17, 2020
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.
- Cluster: BiotechnologyA cluster of topics related to biotechnology.